Single Agent Abraxane as Second Line Therapy in Bladder Cancer

NCT00683059 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Transitional Cell Carcinoma

Interventions

DRUG: Paclitaxel

Sponsor

Sunnybrook Health Sciences Centre

Collaborators

[object Object]